Share on StockTwits
 

InterMune (NASDAQ:ITMN) was downgraded by analysts at UBS AG to a “market perform” rating in a research report issued to clients and investors on Wednesday, American Banking and Market News reports. They currently have a $43.00 price target on the stock, up from their previous price target of $19.00. UBS AG’s price objective would suggest a potential upside of 13.76% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. Analysts at Goldman Sachs raised their price target on shares of InterMune to $40.00 in a research note on Wednesday. Separately, analysts at Canaccord Genuity raised their price target on shares of InterMune from $22.00 to $46.00 in a research note on Wednesday. They now have a “buy” rating on the stock. Finally, analysts at Leerink Swann downgraded shares of InterMune from an “outperform” rating to a “market perform” rating in a research note on Wednesday. They now have a $41.00 price target on the stock. They noted that the move was a valuation call. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. InterMune currently has an average rating of “Buy” and a consensus price target of $34.00.

Shares of InterMune (NASDAQ:ITMN) traded down 14.87% during mid-day trading on Wednesday, hitting $32.18. 9,480,832 shares of the company’s stock traded hands. InterMune has a one year low of $8.41 and a one year high of $38.73. The stock’s 50-day moving average is $15.75 and its 200-day moving average is $14.57. The company’s market cap is $2.887 billion. InterMune also saw some unusual options trading on Tuesday. Stock investors bought 25,056 call options on the company. This represents an increase of 667% compared to the typical daily volume of 3,267 call options.

InterMune, Inc (NASDAQ:ITMN), is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.